Stock of the Day

December 6, 2024

Clarivate (CLVT)

$2.05
+$0.03 (+1.2%)
Market Cap: $1.29B

About Clarivate

Clarivate Plc operates as an information services provider in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. It operates through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers Web of Science and InCites, that analyzes and explores the academic research landscape and manages research information; ProQuest One and Ebook Central that provides comprehensive content collections to institutions in a cost-effective manner; and Alma and Polaris, that manages academic resources and services, connect users, and support research publications. It also provides Patent and Trademark Renewals, that supports paralegal and admin tasks throughout the patent and trademark protection and maintenance process; CompuMark and Derwent, that supports critical decisions around patent and trademark protection, risk, and value creation throughout the innovation and brand lifecycle; IPFolio and Foundation IP that creates a structured environment for the protection and management of global patent and trademark assets. In addition, the company offers Cortellis Competitive Intelligence and Cortellis Drug Discovery Intelligence, that supports the development of new drugs and medical devices from discovery to clinical trials; Cortellis Regulatory Intelligence and OFF-X to monitor drug safety issues and adhere to regulatory protocols; Real World Data and Optimize that inform commercial launch strategy and set pricing for optimal reimbursement. It serves corporations, universities, law firms, government agencies, public libraries, and other professional services organizations. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.

Today's Trend

Clarivate PLC (NYSE: CLVT) is under pressure as investors weigh a mixed second-quarter report against a series of analyst price-target reductions. Although earnings exceeded expectations and management reaffirmed its 2026 outlook, revenue declined year over year and missed estimates, while the target cuts suggest limited near-term confidence.

  • Clarivate reported second-quarter adjusted EPS of $0.19, ahead of the $0.17–$0.18 analyst consensus and up from $0.18 a year earlier. Management also reaffirmed its 2026 financial outlook and cited progress on its Value Creation Plan. Clarivate Reports Second Quarter 2026 Results
  • Stifel lowered its price target from $6.00 to $5.00 but retained a “buy” rating, implying substantial potential upside from recent trading levels. Benzinga analyst note
  • The company is sharpening its strategic focus through the previously announced divestiture of its Life Sciences & Healthcare segment, a move intended to improve its financial profile but which also changes the business mix. Clarivate Reports Second Quarter 2026 Results
  • Michael Easton will become Clarivate’s chief financial officer on August 8, succeeding Jonathan Collins, who is leaving to pursue another opportunity. Easton is an experienced Clarivate executive, which may support continuity, but the leadership transition adds uncertainty. Clarivate Appoints Michael Easton as Chief Financial Officer
  • Second-quarter revenue of $587.3 million fell 5.5% year over year and missed the $589.7 million consensus estimate. The revenue decline, along with Clarivate’s negative net margin, offsets some of the earnings beat. Clarivate Earnings Report
  • Citigroup and Goldman Sachs both moved to “neutral” and reduced their price targets to $2.50 and $2.60, respectively, from $2.80 and $2.90. The coordinated revisions are likely weighing on sentiment despite both targets remaining above recent levels. Benzinga analyst notes
← Previous Stock of the DayNext Stock of the Day →